{"doi":"10.1210/er.2000-0001","title":"The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance","abstract":null,"journal":"Endocrine Reviews","year":2003,"id":593398,"datarank":0.9251274736332513,"base_score":6.1675164908883415,"endowment":6.1675164908883415,"self_citation_contribution":0.9251274736332513,"citation_network_contribution":0.0,"self_endowment_contribution":0.9251274736332513,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":476,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":2,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1518732,"name":"Steven W. J. Lamberts","orcid":null,"position":1,"is_corresponding":false},{"id":1518731,"name":"Leo J. Hofland","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance","abstract":"Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors. Nevertheless, although somatostatin analogs effectively control hormonal hypersecretion by GH-secreting pituitary adenomas, islet cell tumors, and carcinoid tumors, significant differences are observed among patients with respect to the efficacy of treatment. This may be related to a differential expression of somatostatin receptor subtypes among tumors. In addition, the property of somatostatin receptor subtypes to undergo agonist-induced internalization has important consequences for visualizing, as well as for therapy, of receptor-positive tumors using radioisotope- or chemotherapeutic-compound-coupled somatostatin analogs. This review covers the pathophysiological role of somatostatin receptor subtypes in determining the efficacy of treatment of patients with somatostatin receptor-positive tumors using somatostatin analogs, as well as the preclinical and clinical consequences of agonist-induced receptor internalization for somatostatin receptor-targeted radio- and chemotherapy. Herein, the development and potential role of novel somatostatin analogs is discussed.","is_dataset_classified":null,"base_score":6.1675164908883415,"endowment":6.1675164908883415,"datacite_reuse_total":2,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"12588807","pmcid":null,"openalex_id":"https://openalex.org/W2140741951","authors":[],"funders":[],"total_grants":0,"fwci":17.2986,"citation_percentile":0.99489969,"influential_citations":0,"citation_trend":[{"year":2012,"count":36},{"year":2013,"count":34},{"year":2014,"count":22},{"year":2015,"count":22},{"year":2016,"count":18},{"year":2017,"count":16},{"year":2018,"count":19},{"year":2019,"count":11},{"year":2020,"count":16},{"year":2021,"count":12},{"year":2022,"count":17},{"year":2023,"count":12},{"year":2024,"count":9},{"year":2025,"count":7},{"year":2026,"count":6}],"oa_status":"bronze","license":"other-oa","oa_locations":[{"url":"https://academic.oup.com/edrv/article-pdf/24/1/28/8860737/edrv0028.pdf","host_type":"journal"},{"url":"https://academic.oup.com/edrv/article-pdf/24/1/28/8860737/edrv0028.pdf","host_type":"publisher"},{"url":"http://academic.oup.com/edrv/article-pdf/24/1/28/8860737/edrv0028.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1210/er.2000-0001","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/12588807","host_type":"repository"},{"url":"https://pure.eur.nl/en/publications/4f5143bf-cbd0-4ca4-a899-6e75552d90f1","host_type":"repository"},{"url":"http://hdl.handle.net/1765/10105","host_type":"repository"},{"url":"http://repub.eur.nl/pub/10105","host_type":"repository"},{"url":"https://pure.eur.nl/files/46508185/12588807.pdf","host_type":"repository"}],"fields_of_study":["Neuroendocrine Tumor Research Advances","Pituitary Gland Disorders and Treatments","Neuroblastoma Research and Treatments"],"mesh_terms":["Animals","Drug Resistance","Humans","Neoplasms","Somatostatin","Tachyphylaxis","Gene Expression","Receptors, Somatostatin","Radiopharmaceuticals"],"keywords":["Somatostatin receptor","Somatostatin","Somatostatin receptor 1","Somatostatin receptor 2","Somatostatin receptor 3","Agonist","Internalization","Receptor","Internal medicine","Endocrinology","Neuroendocrine tumors","Cancer research","Octreotide","Biology","Medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.26554424.v1","title":"Additional file 1 of Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26554424","title":"Additional file 1 of Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T10:44:40.893454Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}